早期痴呆（轻度认知障碍）的评估

Evaluation of Early Dementia (Mild Cognitive Impairment).

作者信息

Osorio R S, Berti V, Mosconi L, Li Y, Glodzik L, De Santi S, de Leon M J

机构信息

Department of Psychiatry, Center for Brain Health, Silberstein Alzheimer's Institute, Center of Excellence on Brain Aging, NYU Langone Medical Center, 145 East 32nd Street, 5th Floor, New York, NY 10016, USA; Department of Pathology and Psychiatry, Alzheimer's Disease Center, Silberstein Alzheimer's Institute, Center of Excellence on Brain Aging, NYU Langone Medical Center, 145 East 32nd Street, 2nd Floor, New York, NY 10016, USA; Alzheimer's Disease Research Unit, CIEN Foundation-Reina Sofia Foundation, Carlos III Institute of Health, Valderrebollo 5, (Complejo Alzheimer), PAU de Vallecas, Madrid 28031, Spain.

Department of Psychiatry, Center for Brain Health, Silberstein Alzheimer's Institute, Center of Excellence on Brain Aging, NYU Langone Medical Center, 145 East 32nd Street, 5th Floor, New York, NY 10016, USA; Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Viale Morgagni 85, Florence 50134, Italy.

出版信息

PET Clin. 2010 Jan;5(1):15-31. doi: 10.1016/j.cpet.2009.12.003. Epub 2010 May 27.

DOI:10.1016/j.cpet.2009.12.003

PMID:27157481

Abstract

Early diagnosis of Alzheimer disease (AD) is one of the major challenges for the prevention of this dementia. The pathologic lesions associated with AD develop many years before the clinical manifestations of the disease become evident, during a likely transitional period between normal aging and the appearance of first cognitive symptoms. AD biomarkers are needed not only to reveal these early pathologic changes but also to monitor progression in cognitive and behavioral decline and brain lesions. PET neuroimaging can reliably assess indirect and direct aspects of the molecular biology and neuropathology of AD. This article reviews the use of [18F] 2-fluoro-2-deoxy-D-glucose-PET and amyloid PET imaging in the early detection of AD.

摘要

阿尔茨海默病（AD）的早期诊断是预防这种痴呆症的主要挑战之一。与AD相关的病理病变在疾病临床表现明显之前多年就已出现，这一时期可能处于正常衰老与首次认知症状出现之间的过渡阶段。AD生物标志物不仅需要揭示这些早期病理变化，还需要监测认知和行为衰退以及脑病变的进展。PET神经成像能够可靠地评估AD分子生物学和神经病理学的间接和直接方面。本文综述了[18F]2-氟-2-脱氧-D-葡萄糖PET和淀粉样蛋白PET成像在AD早期检测中的应用。